2017-05-05 |
1 |
|
expiration of U.S. Patent Nos. 7,807,689 (“the ’689 patent”), 8,173,663 (“the ’663 patent”),
8,288,539 (…regulations, the ’689 patent,
the ’663 patent, the ’539 patent, and the ’638 patent are listed in the Orange… (“the ’539 patent”), and 8,900,638 (“the ’638 patent”) (collectively, the “patents-in-
suit”).
…attendant FDA regulations, the ’689 patent,
the ’663 patent, and the ’539 patent are listed in the FDA publication…attendant FDA regulations, the ’689 patent,
the ’663 patent, and the ’539 patent are listed in the Orange Book |
External link to document |
2020-02-04 |
126 |
Opinion |
double patenting.
17. Claims 4 and 12 of U.S. Patent No. 7,807,689 are valid patent claims.…Torrent.”)
Plaintiffs own U.S. Patent No. 7,807,689 (“the ’689 patent”), which is listed in the Orange…second patent for claims that are not
patentably distinct from the claims of the first patent. It …claims in a second patent not
patentably distinct from the claims of the first patent.
The obviousness-type… claims 4 and 12 of the ’689 patent. A bench
trial on Defendants’ patent invalidity defenses to infringement |
External link to document |
2021-02-16 |
136 |
Opinion - USCA |
challenges to claims 4 and 12 of U.S. Patent No.
7,807,689, owned by Takeda. 1 See Takeda Pharm… or non-statutory obviousness-type double patenting. In
their appeal, Appellants challenge… Torrent presents two obviousness-type double patent-
ing theories using Feng’s 2 F162 …not
2 Feng refers to U.S. Patent No. 7,723,344.
3 Böhm refers…J.A. 33496–715
(“Mark 2004,” another patent reference pertaining to xan-
thine-based |
External link to document |
2019-05-06 |
77 |
|
claims and counterclaims pertaining to U.S. Patent No. 8,900,638. Signed by Judge Stanley R. Chesler on 5…
13 February 2020
2:17-cv-03186
830 Patent
None
District Court, D. New Jersey |
External link to document |
2019-09-10 |
91 |
Summary Judgment |
4 and 12 of Takeda’s U.S. Patent No. 7,807,689 (“the ’689 patent”) patent are
not invalid; (2) making…on Validity of Claims 4 & 12 of U.S. Patent No.
7,807,689, and the Certification of Christopher J.…0159, will infringe Claims 4 and 12 of the ’689 patent; (3) making,
using, offering to sell, or selling…0160, will infringe Claims 4 and 12 of the ’689 patent; (4) making, using,
offering to sell, or selling…0161, will infringe Claims 4 and 12 of the ’689 patent; (5) making, using,
offering to sell, or selling |
External link to document |
2019-09-10 |
93 |
Declaration of C. Harnett and Exhibits 1-14 |
and particularly type 2 diabetes. (U.S. Patent No. 6,699,871;
WO2003/004498 A1, also assigned to… particularly type 2 diabetes. (See U.S. Patent No. 6,699,871
assigned to Merck.)
140…, 1998 IndAlo0001036
U.S. Patent No. 6,699,871 to Edmondson et al., Beta-Amino IndAlo0079268…14, 1998 IndAlo0001036
U.S. Patent No. 6,699,871 to Edmondson et al., Beta-Amino IndAlo0079268…689 patent, the
’539 patent, and the ’663 patent, are the WO ’420 publication/ CA ’730 patent and |
External link to document |